StockWatch
·

BODAL CHEMICALS LTD. Q2 FY27 Results

BODALCHEMQ2 FY27 Results
Filing
Result:Good· Market: Up#Base effect#Margin expansion#Cost led

Outlook: Optimistic · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue863.3721.8%79.7%
Total Income883.9623.6%76.7%
Expenditure793.9717.4%60.5%
PBT90.00130.1%1521.0%
Net Profit81.44168.1%1259.0%
OPM12.39%2.67pp7.61pp
NPM9.21%4.96pp8.01pp
EPS6.48168.9%1278.7%
View full financials

Revenue grew a strong 79.7% YoY with real margin expansion (expenses fell to 89.8% of income from 98.9%) and adjusted PAT up ~1047%, but the jump is off a depressed 1.2% NPM base a year ago, capping it short of a true standout.

BODAL CHEMICALS · Q2 FY2027 · THE VERDICT

The ₹81 Crore Quarter Riding a Commodity Super-Cycle That Won't Last

Bodal's Q2 net profit of ₹81.4 crore looks stellar, but ₹20–22 crore is one-off income from land sales and government subsidies. The real profit is ₹60 crore — and it depends entirely on H-acid export prices staying elevated and crude oil not falling. When they do, margins revert to 11–12%.

06 Nov 2026 · 6 min read
Reported PAT

₹81.4 Cr

+1259% YoY

Extraordinary items

~₹20–22 Cr

land sales, subsidies

Normalized PAT

~₹60 Cr

+20–25% YoY organic

OPM delivered

12.4%

vs 14.4% claimed

On the surface, Q2 FY27 looks like a blowout: ₹81.4 crore net profit, up 1259% year-on-year. But that headline number is a mirage. Strip out ₹20–22 crore of one-off items — land sales in Punjab, government subsidies, and other exceptional income — and Bodal's normalized quarterly profit is closer to ₹60 crore. That's strong, but it reframes the quarter entirely: a solid recovery on commodity tailwinds, not a structural inflection.

Where the profit really came from

Revenue of ₹863.4 crore grew 79.7% year-on-year, driven by two forces. First, H-acid (a dye intermediate) prices surged to INR900 per kg in Q2 — driven by China's environmental crackdowns on dye capacity combined with elevated crude oil costs. Second, dyestuff volume ramped 42% to 5,314 MT, as Bodal leveraged its integrated model (40% of H-acid is captive for in-house dyestuff production). The combination is potent: volumes up and prices up.

But here's the margin gap: management claimed a 14.4% EBITDA margin in Q2, yet the delivered operating profit margin was 12.4%. That 2-percentage-point shortfall is real — it signals input cost inflation (sulfur, aniline, crude) ate into the gross margin despite higher selling prices. When crude is $70–80 and H-acid is INR1,600–1,800, it works. When crude normalizes to $60–70, that margin grinds to 11–12%, per management's own scenario analysis.

Management's key claims vs. what holds up in the numbers

H1 FY27 net profit ₹112 Cr, EBITDA ₹203 Cr (114% YoY growth)

Standalone H1 ₹109 Cr, consolidated ₹112 Cr per CFO; prior FY26 H1 was loss

Supported

Dyestuff volume grew 42% H1, Q2 revenue ₹212 Cr (60% QoQ)

Production 5,314 MT Q2 vs 3,742 YoY (42% confirmed); sales value scaling

Supported

FY27 revenue ₹3,000+ Cr achievable at 14–15% EBITDA margin

H1 ₹1,599 Cr; H2 at same growth would deliver ~₹2,700 Cr full-year

Overstated

H-acid prices should sustain through Jan on China structural shift

Currently INR440–450 (down from INR900 peak); management hedged on Feb–Mar

Partially supported

The real story: working capital strain and immature segments

What management did not emphasize on the call, but what the cash flow makes clear, is that receivables exploded. At ₹1,600 crore, they are up 70–80% in H1 alone. The CFO acknowledged a ₹2,000 crore 'cash receivable cycle' — meaning the company is essentially financing its customer base as order flow surges. This is classic high-growth strain: turnover is up 70–80%, so working capital gets locked up. Once growth steadies, receivables should normalize — but if demand softens or collection drags, it's a cliff event for cash flow.

Meanwhile, two segments that management hopes will drive margin expansion are still immature. Benzene derivatives — expected to materially contribute in Q3+ — was only 50% utilized in Q2 and 'just started contributing to top line.' TCCA (trichloroisocyanuric acid), benefiting from anti-dumping duty protection, is still break-even; expansion capacity was held up by Chinese equipment export restrictions, and local sourcing is being pursued but timelines are vague. Neither is margin-accretive today.

What changed on this call

  • Benzene ramp immature: 50% utilization in Q2, minimal EBITDA contribution (was expected sooner)

  • TCCA expansion delayed: Chinese equipment sourcing blocked; pivot to local procurement, but no firm timeline

  • H-acid pricing held at INR1,600–1,800, but management hedged Feb–Mar sustainability

  • FY27 ₹3,000+ Cr revenue target remains 'achievable,' but requires 15–20% H2 growth (tight)

  • Management tone shifted mid-call: confident on opening, grew defensive on receivables risk and capex timing

The bull-bear ledger

  • H-acid export super-cycle is real (China environmental crackdowns restrict local dye capacity; India sole export outlet)

  • Dyestuff volume growth (42% YoY) and integrated model (40% captive H-acid) provide cost advantage

  • Anti-dumping duty on TCCA imports gives near-monopoly pricing power if expansion executes

  • Q2 net profit includes 22–25% one-off items; organic profit ₹60 Cr, not ₹81 Cr

  • Receivables ₹1,600 Cr (+70–80% HY) is a working capital shock if demand softens or collection slows

  • Margin sustainability hinges on crude staying $70–80; below that, EBITDA margin contracts to 11–12%

  • Benzene and TCCA immature; both expected to add margin, but unproven and capex-dependent

Risks, ranked by how much they should concern a holder

Key risks to monitor

Commodity price exposure (crude, H-acid)

High

If Brent crude falls below $70/bbl or China brings H-acid capacity online, EBITDA margin compresses from 14–15% to 11–12%. No pricing power in input-constrained environment.

Receivables realization and working capital shock

High

₹1,600 Cr receivables (+70–80% HY) is unsustainable growth. If demand softens or customer collection lags, cash flow headwind and potential write-offs.

Chinese equipment export delays block capex

Medium-High

TCCA expansion contingent on procuring equipment locally (original China order blocked). Timeline vague ('next few months'). If capex misses, margin upside deferred.

Benzene derivatives ramp underperforms

Medium

At 50% utilization in Q2, 'just started contributing.' If ramp stalls or margins disappoint, FY28 margin guidance (14–15%) becomes unachievable.

China dye/chemical capacity normalization

Medium

If China resolves environmental restrictions or invests in new capacity, H-acid export super-cycle ends. Pricing power erodes; margin reverts to 11–12% baseline.

How the street is positioned

Bodal's stock has repriced sharply: at ₹161.8 as of 2026-11-05, it is down 22% from its all-time high of ₹207.45, despite the company delivering strong Q2 results (+80% revenue YoY, +1259% profit YoY). This 22% drawdown signals the street's skepticism about margin sustainability and working capital risks. The stock remains up 292% from its 52-week low of ₹41.25, but has failed to hold the recent highs — a classic 'sell the news' pattern when a commodity super-cycle appears priced in.

Institutional positioning reflects this caution. FII ownership has declined to 0.02% (down 13 basis points quarter-on-quarter), suggesting institutions are trimming exposure as the upside narrative becomes crowded and the downside risks (crude normalization, receivables stress) come into focus. There is no DII participation. Bulk deals over the past six months show mostly algorithmic trading — no insider selling or promoter activity. Promoter ownership remains stable at 57%, which is neutral; neither a vote of confidence nor concern.

Volume is increasing, suggesting retail interest, but the price action — failing to hold the highs despite strong earnings — is a vote against the bull case. The street's read: Q2 earnings are real, but the margin assumptions (14–15% EBITDA, ₹3k+ Cr FY27 revenue, ₹3.5–4k Cr FY28) are too optimistic and dependent on commodity prices and a Chinese structural shift that may not persist.

The debate

The bull case: Bodal is the largest Indian dye intermediate producer, benefiting from a structural shift in China (environmental crackdowns on local dye capacity) that is driving H-acid exports. Dyestuff volume is ramping (42% YoY), margins are expanding (14–15% EBITDA achievable), and anti-dumping duty protection on TCCA is creating near-monopoly economics. If management executes on capex (benzene, TCCA) and crude stays $70–80, the company can deliver ₹3k+ Cr FY27 revenue and ₹3.5–4k Cr by FY28 at sustained 14–15% margins. Valuation is still reasonable relative to the earnings jump.

The bear case: Q2 earnings are inflated by ₹20–22 Cr of one-off items and commodity tailwinds. Strip those out and normalized PAT is ₹60 Cr, still good but unspectacular. Receivables have ballooned to ₹1,600 Cr (+70–80%), signaling working capital stress; if demand softens, it's a cash flow cliff. H-acid pricing is dependent on crude staying elevated and China's environmental restrictions persisting — both cyclical assumptions, not structural. Benzene and TCCA are immature; both expected to drive FY28 growth, but capex is delayed (Chinese equipment restrictions) and timelines vague. If crude falls to $60–70 or China brings capacity online, EBITDA margin reverts to 11–12%, and FY28 guidance misses by 25%+. Stock is down 22% from highs for a reason.

The honest read: Bodal is not a 14–15% EBITDA margin compounder; it is a commodity-leveraged cyclical with immature growth segments. Q2 is a good quarter in a favorable cycle, but sustainability is contingent on macro inputs (crude, China policy) staying benign. The ₹60 Cr normalized PAT is real and represents solid recovery from FY26 weakness. But the ₹81 Cr headline is misleading. Receivables are a legitimate concern — if they don't normalize in one-to-two quarters, working capital will become a material headwind. Benzene and TCCA ramps should deliver margin accretion by FY28, but capex risks (Chinese equipment delays, local sourcing timelines) are real. The stock's 22% decline from ATH is justified by execution risk and cycle risk, not overvaluation. A Hold is the right stance until receivables stabilize and capex timelines clarify.

What to watch next

Three concrete things that resolve the debate
  • 1 · Q3 receivables and cash flow

    If receivables stabilize (normalize to ₹1,200–1,300 Cr range) and operating cash flow improves, the working capital scare is overblown. If they stay elevated or grow, it signals customer payment terms are being extended and collection risk is real.

  • 2 · Benzene ramp execution in Q3–Q4

    From 50% utilization in Q2 to full capacity and meaningful EBITDA contribution. If utilization hits 70–80%+ and margins improve, the FY28 growth story gains credibility. If it stalls, FY28 guidance becomes unachievable.

  • 3 · Crude price and H-acid realization

    H-acid is currently INR440–450 per kg (down from INR900 peak). If it stabilizes here and crude stays $70–80, the 14–15% margin is achievable. If crude falls to $60 or H-acid falls below INR350, margins compress to 11–12% and FY27 guidance becomes optimistic.

Bodal's Q2 is a good quarter in a commodity super-cycle, not a structural inflection. Reported profit of ₹81.4 crore is strong in headline, but strip ₹20–22 crore of one-offs and it's ₹60 crore — solid, but not exceptional. The company is betting FY27–FY28 on sustained H-acid export super-cycle (China structural shift + elevated crude) and immature segment ramps (benzene 50% utilization, TCCA break-even). Working capital stress (receivables +70–80% HY) is a real concern if demand softens.

The stock's 22% decline from all-time high despite strong results is the street's way of saying: this upside is priced in, and the downside risks (commodity cycle, receivables realization, capex delays) are real. Management quality is credible on numbers but increasingly defensive on sustainability — a signal they are hedging their own guidance.

The number to track from here is normalized PAT (which will reveal when one-offs end), receivables turnover (which will signal working capital health), and crude prices (which will tell you if margin guidance is achievable). Until those clarify, Hold is the right stance.

Informational and educational content only. Not investment advice.